Citations

Showing 10 of 108083 citations.

Paging the Clinical Informatics Community: Respond STAT to Dobbs v. Jackson's Women's Health Organization
Ravi, Akshay , Weia, Benjamin , Aarts, Jos , Ahmad, Hasan B., Araj, Ellen, Bauml, Julie A., Boyd, Andrew D. , Brecht-Doscher, Aimee, Butler‐Henderson, Kerryn , Butte, Atul J. , Cardilo, Anthony B., Chilukuri, Nymisha , Cho, Mildred K. , Cohen, Jenny K., Craven, Catherine K. , Crusco, Salvatore, Dadabhoy, Farah Z. , Dash, Dev , DeBolt, Claire , Fayanju, Oluseyi A, Fochtmann, Laura J. , Graham, Justin V., Hanna, John , Hofford, Mackenzie , Hron, Jonathan D. , Huang, Sean S, Jackson, Brian R. , Kaplan, Bonnie , Kelly, William R. , Ko, Kyungmin, Kurapati, Nikhil , Labbad, Gabriel , Lee, Julie , Leitner, Stefano, Liao, Zachary C , Melnick, Edward R. , Muniyappa, Anoop , Murray, Sara G. , Nichols-Johnson, Victoria, Novak, Laurie L. , Ogan, William Scott , Ozeran, Larry, Pageler, Natalie M. , Pandita, Deepti , Perumbeti, Ajay, Petersen, Carolyn , Pierce, Logan , Puttagunta, Raghuveer, Ramaswamy, Priya , Rogers, Kendall, Ryan, Angela M., Sarabu, Chethan , Shaw, Kate A. , Spector, Jacob D. , Starren, Justin , Stoffel, Michelle , Swanson, Karl , Tomes, Adrian, Unertl, Kim M. , Weon, Jenny L. , Wiley, Kevin , Winkelstein, Peter , Wong, Jenson, Xie, James , Yarahuan, Julia , Yung, Nathan , Zera, Chloe , Sadasivaiah, Shobha , Boyd, Andrew D , Melnick, Edward R , Petersen, Carolyn , Arvisais‐Anhalt, Simone , Benham‐Hutchins, Marge , Brecht-Doscher, Aimee, Elkin, Peter L. , Hersh, William , Kelly, William, Koppel, Ross , Lehmann, Christoph U. , Medford, Richard J , Neinstein, Aaron Barak , Rosenbloom, S. Trent , Ryan, Angela, Saleh, Sameh Nagui , Schreiber, Richard , Sim, Ida , Sirintrapun, Sahussapont Joseph , Solomonides, Anthony , Subbian, Vignesh , Trang, Karen , Whooley, Mary A. , Williamson, Drew F. K. , Ratanawongsa, Neda

Mayo Clinic

Applied Clinical Informatics | December 19, 2022 | Volume: 14 | Issue: 01 | Pages: 164-171

10.1055/a-2000-7590 | PMID 36535703 Get It

Editorial Commentary
Pessoa, Rodrigo Rodrigues , Ballon‐Landa, Eric , Kim, Simon P.

Mayo Clinic

Urology Practice | December 19, 2022 | Volume: 10 | Issue: 1 | Pages: 47-47

10.1097/upj.0000000000000363.01 | PMID 37103454 Get It

American Radium Society (ARS) Appropriate Use Criteria (AUC) for Extrahepatic Cholangiocarcinoma
Tchelebi, Leila T. , Levy, Anna T., Anker, Christopher J. , Kennedy, Timothy J., Grodstein, Elliot , Hallemeier, Christopher L. , Kumar, Rachit , Lee, Percy, Williams, Vonetta M. , Sharma, Navesh , Russo, Suzanne , Achilonu, Conrad Chibunna , Tchelebi, Leila , Achilonu, Conrad C , Jethwa, Krishan R. , Hallemeier, Christopher Leigh , Jabbour, Salma K , Kim, Ed, Lee, Percy , Small, William , Russo, Suzanne

Mayo Clinic

American Journal of Clinical Oncology | December 19, 2022 | Volume: 46 | Issue: 2 | Pages: 73-84

10.1097/coc.0000000000000969 | PMID 36534388 Get It

Although uncommon, extrahepatic cholangiocarcinoma (EHCC) is a deadly malignancy, and the treatment approaches remain controversial. While surgery remains the only cure, few patients are candidates for resection up front, and there are high rates of both local and distant failure following resection. Herein, we systematically review the available evidence regarding treatment approaches for patients with EHCC, including surgery, radiation, and chemotherapy. The evidence regarding treatment outcomes was assessed using the Population, Intervention, Comparator, Outcome, and Study design (PICOS) framework. A summary of recommendations based on the available literature is outlined for specific clinical scenarios encountered by providers in the clinic to guide the management of these patients.
Reliability of the ISAKOS Modification to Subclassify Rockwood Type III Acromioclavicular Joint Injuries
Garcia, Ausberto Velasquez , Abdo, Glen , Velasquez Garcia, Ausberto

Mayo Clinic

Orthopaedic Journal of Sports Medicine | December 19, 2022 | Volume: 10 | Issue: 12 | Pages: No page available

10.1177/23259671221133379 | PMID 36570359 Get It

Background: To improve clinical management, the International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine (ISAKOS) developed a specific subclassification of Rockwood type III acromioclavicular (AC) injuries: IIIA (no overriding distal clavicle) and IIIB (overriding distal clavicle). Purpose/Hypothesis: The study aimed to determine the inter- and intraobserver reliability of the radiographic classification proposed by ISAKOS for AC injuries. It was hypothesized that the strength of agreement for the ISAKOS modification will be substantial to almost perfect. Study Design: Cohort study (diagnosis); Level of evidence, 3. Methods: We evaluated 40 radiographs of all types of AC joint injuries from patients at a single institution. The images were distributed to 6 shoulder and elbow fellowship–trained orthopaedic surgeons, along with standardized assessment questionnaires. The evaluators measured the bilateral coracoclavicular distance and the coracoclavicular ratio and classified the severity of the injuries according to the modified ISAKOS Rockwood classification. Four of the surgeons repeated the evaluation 6 weeks later to calculate intraobserver agreement. The kappa (κ) statistic was calculated for categorical inter- and intraobserver reliability. Intraclass correlation coefficient (ICC) estimates were calculated for the reliability of the coracoclavicular distance measurement. A 2-tailed test was performed to assess statistical significance. Results: Overall interobserver agreement was substantial (κ = 0.637; 95% CI, 0.595-0.680) among the 6 evaluators, and intraobserver agreement was also substantial among the 4 evaluators (κ = 0.616; 95% CI, 0.549-0.638). The interobserver agreement for evaluating types IIIA and IIIB was fair (κ = 0.215; 95% CI, 0.135-0.295) and moderate (κ = 0.473; 95% CI, 0.393-0.553), respectively. The agreement on the coracoclavicular distance measurements was excellent among the 6 evaluators on both the affected side (ICC, 0.982; 95% CI, 0.970-0.990) and the unaffected side (ICC, 0.930; 95% CI, 0.894-0.958). Conclusion: Substantial agreement was found when categorizing AC joint injuries using the ISAKOS modification of the Rockwood classification, with excellent reliability demonstrated for the quantitative assessment of vertical displacement of the clavicle. Visual examination was unreliable in differentiating type IIIA injuries from type IIIB injuries.
Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
Mondello, Patrizia , Novak, Joseph P. , Wenzl, Kerstin , Yang, Zhi-Zhang , Jalali, Shahrzad , Krull, Jordan E. , Braggio, Esteban , Dasari, Surendra , Manske, Michelle K. , Abeykoon, Jithma P. , Sarangi, Vivekananda , Kapoor, Prashant , Paulus, Aneel , Reeder, Craig B. , Chanan‐Khan, Asher , Kyle, Robert A. , Novak, Anne J. , Ansell, Stephen M. , Paludo, Jonas , Novak, Joseph P , Wenzl, Kerstin , Yang, Zhi-Zhang , Jalali, Shahrzad , Krull, Jordan E , Braggio, Esteban , Dasari, Surendra , Manske, Michelle K , Abeykoon, Jithma P , Sarangi, Vivekananda , Kapoor, Prashant , Paulus, Aneel , Reeder, Craig B , Ailawadhi, Sikander , Chanan-Khan, Asher , Kyle, Robert A , Gertz, Morie A , Novak, Anne J , Ansell, Stephen M , Mondello, Patrizia , Paludo, Jonas , Ailawadhi, Sikander , Gertz, Morie A.

Mayo Clinic

Clinical Cancer Research | December 19, 2022 | Volume: 29 | Issue: 5 | Pages: 957-970

10.1158/1078-0432.ccr-22-2215 | PMID 36534518 Get It

Abstract Purpose: IgM monoclonal gammopathy of undetermined significance (MGUS) and Waldenström macroglobulinemia (WM) represent a disease spectrum with highly varied therapeutic management, ranging from observation to chemoimmunotherapy. The current classification relies solely on clinical features and does not explain the heterogeneity that exists within each of these conditions. Further investigation is warranted to shed light on the biology that may account for the clinical differences. Experimental Design: We used bone marrow (BM) clonal CD19+ and/or CD138+ sorted cells, matched BM supernatant, and peripheral blood serum from 32 patients (7 MGUS, 25 WM) to perform the first multi-omics approach including whole-exome sequencing, RNA sequencing, proteomics, metabolomics, and mass cytometry. Results: We identified three clusters with distinct pathway activation, immune content, metabolomic, and clinical features. Cluster 1 included only patients with WM and was characterized by transcriptional silencing of genes involved in cell cycle and immune response, enrichment of mitochondrial metabolism, infiltration of senescent T effector memory cells, and aggressive clinical behavior. Genetic/structural alterations of TNFAIP3 were distinct events of this cluster. Cluster 2 comprised both MGUS and WM patients with upregulation of inflammatory response, senescence and glycolysis signatures, increased activated T follicular helper and T regulatory cells, and indolent clinical behavior. Cluster 3 also included both MGUS and WM patients and exhibited intermediate features, including proliferative and inflammatory signaling, as well as glycolysis and mitochondrial metabolism. Conclusions: We have identified three distinct molecular clusters, suggesting a potential biologic classification that may have therapeutic implications.
Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Visvanathan, Kala , Cope, Leslie , Fackler, Mary Jo , Considine, Michael , Sokoll, Lori J. , Carey, Lisa A. , Forero-Torres, Andres , Ingle, James N. , Lin, Nancy U. , Nanda, Rita , Storniolo, Anna Maria , Tulac, Suzana , Venkatesan, Neesha , Wu, Natalie C. , Marla, Sudhakar , Campbell, Scott , Bates, Michael , Umbricht, Christopher B. , Ingle, J , Sokoll, Lori , Wolff, Antonio C , Sukumar, Saraswati , Carey, Lisa A , Visvanathan, Kala , Lin, Nancy U , Wolff, Antonio C.

Mayo Clinic

Clinical Cancer Research | December 19, 2022 | Volume: 29 | Issue: 4 | Pages: 784-790

10.1158/1078-0432.ccr-22-2128 | PMID 36534524 Get It

Abstract Purpose: We previously demonstrated that high levels of circulating methylated DNA are associated with subsequent disease progression in women with metastatic breast cancer (MBC). In this study, we evaluated the clinical utility of a novel liquid biopsy-breast cancer methylation (LBx-BCM) prototype assay using the GeneXpert cartridge system for early assessment of disease progression in MBC. Experimental Design: The 9-marker LBx-BCM prototype assay was evaluated in TBCRC 005, a prospective biomarker study, using plasma collected at baseline, week 4, and week 8 from 144 patients with MBC. Results: At week 4, patients with MBC with high cumulative methylation (CM) had a significantly shorter median PFS (2.88 months vs. 6.60 months, P = 0.001) and OS (14.52 months vs. 22.44 months, P = 0.005) compared with those with low CM. In a multivariable model, high versus low CM was also associated with shorter PFS (HR, 1.90; 95% CI, 1.20–3.01; P = 0.006). Change in CM from baseline to week 4 (OR, 4.60; 95% CI, 1.77–11.93; P = 0.002) and high levels of CM at week 4 (OR, 2.78; 95% CI, 1.29–5.99; P = 0.009) were associated with progressive disease at the time of first restaging. A robust risk model based on week 4 circulating CM levels was developed to predict disease progression as early as 3 months after initiating a new treatment. Conclusions: The automated LBx-BCM prototype assay is a promising clinical tool for detecting disease progression a month after initiating treatment in women with MBC undergoing routine care. The next step is to validate its clinical utility for specific treatments.
Machine Learning-Based Classification of Abnormal Liver Tissues Using Relative Permittivity
Samaddar, Poulami , Mishra, Anup Kumar , Gaddam, Sunil , Singh, Mansunderbir, Modi, Vaishnavi K., Gopalakrishnan, Keerthy, Bayer, Rachel L., Igreja, Ivone Cristina , Khanal, Shalil , Dey, Shuvashis , Mitra, Dipankar , Roy, Sayan , Arunachalam, Shivaram P. , Igreja Sa, Ivone Cristina , Dey, Shuvashis , Roy, Sayan , Arunachalam, S P , Mishra, Anup , Hirsova, Petra , Kostallari, Enis

Mayo Clinic

Sensors | December 19, 2022 | Volume: 22 | Issue: 24 | Pages: 9919

10.3390/s22249919 | PMID 36560303 Get It

The search for non-invasive, fast, and low-cost diagnostic tools has gained significant traction among many researchers worldwide. Dielectric properties calculated from microwave signals offer unique insights into biological tissue. Material properties, such as relative permittivity (εr) and conductivity (σ), can vary significantly between healthy and unhealthy tissue types at a given frequency. Understanding this difference in properties is key for identifying the disease state. The frequency-dependent nature of the dielectric measurements results in large datasets, which can be postprocessed using artificial intelligence (AI) methods. In this work, the dielectric properties of liver tissues in three mouse models of liver disease are characterized using dielectric spectroscopy. The measurements are grouped into four categories based on the diets or disease state of the mice, i.e., healthy mice, mice with non-alcoholic steatohepatitis (NASH) induced by choline-deficient high-fat diet, mice with NASH induced by western diet, and mice with liver fibrosis. Multi-class classification machine learning (ML) models are then explored to differentiate the liver tissue groups based on dielectric measurements. The results show that the support vector machine (SVM) model was able to differentiate the tissue groups with an accuracy up to 90%. This technology pipeline, thus, shows great potential for developing the next generation non-invasive diagnostic tools.
Metabolic Risk Factors for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Study
Antwi, Samuel O. , Craver, Emily C. , Nartey, Yvonne Ayerki , Sartorius, Kurt , Patel, Tushar , Nartey, Yvonne A , Antwi, Samuel O , Patel, Tushar

Mayo Clinic

Cancers | December 19, 2022 | Volume: 14 | Issue: 24 | Pages: 6234

10.3390/cancers14246234 | PMID 36551719 Get It

Non-alcoholic fatty liver disease (NAFLD) is a fast-growing public health problem and predisposes to hepatocellular carcinoma (HCC) in a significant proportion of patients. Metabolic alterations might underlie the progression of NAFLD to HCC, but the magnitudes of risk and population-attributable risk fractions (PAFs) for various metabolic conditions that are associated with HCC risk in patients with NAFLD are unknown. We investigated the associations between metabolic conditions and HCC development in individuals with a prior history of NAFLD. The study included 11,245 participants in the SEER-Medicare database, comprising 1310 NAFLD-related HCC cases and 9835 NAFLD controls. We excluded individuals with competing liver diseases (e.g., alcoholic liver disease and chronic viral hepatitis). Baseline pre-existing diabetes mellitus, dyslipidemia, obesity, hypertension, hypothyroidism, and metabolic syndrome were assessed. Multivariable-adjusted logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). PAFs were also calculated for each metabolic condition. The results show that diabetes (OR = 2.39, 95% CI: 2.04–2.79), metabolic syndrome (OR = 1.73, 95% CI: 1.49–2.01), and obesity (OR = 1.62, 95% CI: 1.43–1.85) were associated with a higher HCC risk in individuals with NAFLD. The highest PAF for HCC was observed for pre-existing diabetes (42.1%, 95% CI: 35.7–48.5), followed by metabolic syndrome (28.8%, 95% CI: 21.7–35.9) and obesity (13.2%, 95% CI: 9.6–16.8). The major predisposing factors for HCC in individuals with NAFLD are diabetes mellitus, metabolic syndrome, and obesity, and their control would be critically important in mitigating the rising incidence of NAFLD-related HCC.
Metabolomic and Mitochondrial Fingerprinting of the Epithelial-to-Mesenchymal Transition (EMT) in Non-Tumorigenic and Tumorigenic Human Breast Cells
Fernández‐Arroyo, Salvador , Verdura, Sara , Lupu, Ruth , Joven, Jorge , Menéndez, Javier A. , Cuyàs, Elisabet , Fernández-Arroyo, Salvador , Verdura, Sara , Joven, Jorge , Menendez, Javier A , Cuyàs, Elisabet

Mayo Clinic

Cancers | December 19, 2022 | Volume: 14 | Issue: 24 | Pages: 6214

10.3390/cancers14246214 | PMID 36551699 Get It

Epithelial-to-mesenchymal transition (EMT) is key to tumor aggressiveness, therapy resistance, and immune escape in breast cancer. Because metabolic traits might be involved along the EMT continuum, we investigated whether human breast epithelial cells engineered to stably acquire a mesenchymal phenotype in non-tumorigenic and H-RasV12-driven tumorigenic backgrounds possess unique metabolic fingerprints. We profiled mitochondrial–cytosolic bioenergetic and one-carbon (1C) metabolites by metabolomic analysis, and then questioned the utilization of different mitochondrial substrates by EMT mitochondria and their sensitivity to mitochondria-centered inhibitors. “Upper” and “lower” glycolysis were the preferred glucose fluxes activated by EMT in non-tumorigenic and tumorigenic backgrounds, respectively. EMT in non-tumorigenic and tumorigenic backgrounds could be distinguished by the differential contribution of the homocysteine-methionine 1C cycle to the transsulfuration pathway. Both non-tumorigenic and tumorigenic EMT-activated cells showed elevated mitochondrial utilization of glycolysis end-products such as lactic acid, β-oxidation substrates including palmitoyl–carnitine, and tricarboxylic acid pathway substrates such as succinic acid. Notably, mitochondria in tumorigenic EMT cells distinctively exhibited a significant alteration in the electron flow intensity from succinate to mitochondrial complex III as they were highly refractory to the inhibitory effects of antimycin A and myxothiazol. Our results show that the bioenergetic/1C metabolic signature, the utilization rates of preferred mitochondrial substrates, and sensitivity to mitochondrial drugs significantly differs upon execution of EMT in non-tumorigenic and tumorigenic backgrounds, which could help to resolve the relationship between EMT, malignancy, and therapeutic resistance in breast cancer.